相关实验视频
Updated: Jun 5, 2025

Breath Collection from Children for Disease Biomarker Discovery
Published on: February 14, 2019
急性COPD恶化的分子呼吸特征
Sarah Basler1, Noriane A Sievi1, Felix Schmidt1
1Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
分析呼吸生物标志物可以准确预测慢性阻塞性肺病 (AECOPD) 的急性恶化. 在AECOPD期间特定途径的代谢变化为改善诊断和治疗提供了洞察力.
科学领域:
- 肺部医学 肺部医学
- 代谢学 代谢学 代谢学
- 生物标志物发现发现
背景情况:
- 慢性阻塞性肺病 (AECOPD) 的急性恶化表现出显著的个体变异性,并推动疾病的进展.
- 精确的诊断和有效的治疗对于管理AECOPD至关重要.
- 在AECOPD期间了解呼吸中的分子代谢变化可以提高对该疾病及其治疗策略的理解.
研究的目的:
- 在AECOPD期间调查代谢呼吸形状,以识别潜在的生物标志物.
- 为了比较COPD患者的AECOPD和稳定阶段之间的呼吸分子模式.
- 开发一个预测模型来区分AECOPD和稳定状态.
主要方法:
- 在AECOPD和稳定阶段,对COPD患者进行了实时呼吸分析.
- 用尺寸缩小技术和配对的t测试进行了分子呼吸模式比较.
- 途径丰富分析确定了潜在的代谢途径,并使用机器学习模型 (PLS-DA,XGboost) 进行预测.
主要成果:
- 预测AECOPD的灵敏度为82.5%和AUC为0.86.5的AUC.
- 在AECOPD期间,主要的代谢变化观察到在酸,氨酸和氨酸路径中.
- 这些途径与炎症过程有着显著的关联.
结论:
- 在COPD恶化期间发生显著的代谢转变,特别是在与炎症相关的途径中.
- 实时呼气分析为预测AECOPD提供了一种可靠的方法.
- 这种方法有可能提高在管理AECOPD的诊断精度和临床疗效.
更多相关视频
09:19Capturing Actively Produced Microbial Volatile Organic Compounds from Human-Associated Samples with Vacuum-Assisted Sorbent Extraction
Published on: June 1, 2022
08:44Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
Published on: February 2, 2024
相关概念视频
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Assessment of Diffusion and Perfusion
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
COPD: Management Using Bronchodilators and Corticosteroids